在中风后抑郁症中通过maraviroc增强阻断CCR5活性:一项概念验证临床试验
Oren Tene1,2, Jeremy Molad3, Ofer Rotschild3
1Department of Psychiatry, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
BMC neurology
|June 6, 2024
概括
马拉维罗克 (Maraviroc) 是一种CCR5抗剂,它显示出作为治疗中风后抑郁症 (PSD) 的耐受性良好的治疗方法. 这项研究表明,它在减少抑郁症症状方面具有潜在的有效性,因此需要在更大规模的试验中进一步调查.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 脑卒中后抑郁症 (PSD) 显著阻碍了康复和康复.
- 对于PSD,有效的治疗选择有限,造成未满足的临床需求.
- 目前正在探索CCR5抗剂的新疗法机制.
研究的目的:
- 调查马拉维罗克作为PSD的附加治疗的安全性和潜在疗效.
- 在一个概念验证试验中评估Maraviroc基于机制的治疗潜力.
主要方法:
- 一个开放的,为期10周的临床试验,涉及10名患有PSD的患者.
- 每天口服300毫克马拉维罗克,然后进行为期八周的监测期.
- 主要结局:安全性 (不良事件);次要结局:蒙哥马利-阿斯伯格抑郁评分表 (MADRS) 评分的变化.
主要成果:
- 马拉维罗克耐受性很好,没有严重的不良事件或因不耐受性而停止治疗.
- 从基线到第10周的MADRS得分显著下降 (平均变化:16.4 ± 9.3;p < 0.001).
- 五名患者表现出良好的反应,四名患者在三周内实现了缓解;治疗后的得分增加.
结论:
- 每天300毫克马拉维罗克似乎是PSD的安全和潜在有效治疗方法.
- 需要进一步的安慰剂对照研究来证实马拉维罗克在增强PSD治疗中的有效性.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
220
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
220
Retrovirus Life Cycles
45.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.8K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
489
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
489


